Core Insights - The social security fund has invested in 396 stocks by the end of Q2, with 37 stocks held for over 20 consecutive quarters, indicating a focus on long-term investments [1][2] Group 1: Investment Trends - The social security fund has consistently held shares in 204 stocks for over four quarters, with 132 stocks held for more than two years [1] - The longest-held stock is Hualu Hengsheng (华鲁恒升), held for 51 quarters since Q4 2012, with a total holding of 133 million shares, accounting for 6.26% of the circulating shares [1][4] - Other long-term holdings include Zhongyuan Media (中原传媒) and WoW Bio (我武生物), held for 44 and 43 quarters respectively [1] Group 2: Stock Performance - Among the 37 stocks held for over five years, the top holdings by quantity are Changshu Bank (常熟银行) with 206 million shares, Sun Paper (太阳纸业) with 151 million shares, and Hualu Hengsheng with 133 million shares [2] - The stocks with the highest holding ratios include Keri International (科锐国际) at 6.30%, Hualu Hengsheng at 6.26%, and Changshu Bank at 6.23% [2] - In terms of changes in holdings, 12 stocks saw an increase in holdings, with significant increases for Three Squirrels (三只松鼠) at 283.29%, Hongfa Co. (宏发股份) at 76.77%, and Hangyang Co. (杭氧股份) at 42.03% [2] Group 3: Industry Distribution - The 37 stocks are concentrated in the basic chemical, electronics, and automotive industries, with 7, 3, and 3 stocks respectively [3] - The basic chemical sector includes Hualu Hengsheng, Yangnong Chemical (扬农化工), and Blue Sky Technology (蓝晓科技) [3] - The electronics sector includes Transsion Holdings (传音控股), Pengding Holdings (鹏鼎控股), and XW Communication (信维通信) [3] Group 4: Financial Performance - Among the 37 stocks, 24 reported year-on-year profit growth, with notable increases from China Jushi (中国巨石) at 75.51%, Jieput (杰普特) at 73.84%, and New Hecheng (新和成) at 63.46% [3] - Conversely, 12 stocks experienced a decline in net profit, with the largest decreases from Zhongqi Co. (中旗股份) at 240.99%, Sanyou Chemical (三友化工) at 77.64%, and Three Squirrels at 52.22% [3]

Market Overview - The biopharmaceutical sector experienced a decline of 2.85% on August 27, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Wuwei Biotech (300357) saw a significant increase of 5.38%, closing at 30.95 with a trading volume of 299,000 shares and a transaction value of 915 million yuan [1] - Kanghua Biotech (300841) reported a notable decline of 8.89%, closing at 76.60 with a trading volume of 125,200 shares and a transaction value of 993 million yuan [2] - Anke Biotech (300009) also faced a drop of 5.59%, closing at 11.14 with a trading volume of 862,300 shares and a transaction value of 990 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 1.853 billion yuan from institutional investors, while retail investors saw a net inflow of 1.543 billion yuan [2] - The capital flow for individual stocks indicates that Hualan Biotech (002007) had a net inflow of 32.28 million yuan from institutional investors, while it faced a net outflow of 40.67 million yuan from speculative funds [3] - The overall trend shows that retail investors are actively investing in the sector despite the institutional outflows [2][3]

Core Viewpoint - The strong performance of Iwu Biological's stock is driven by its impressive half-year report and a robust growth strategy in the allergy treatment sector [1][2] Financial Performance - Iwu Biological reported a revenue increase to 484 million yuan, with a net profit of 177 million yuan, and a non-recurring net profit growth rate of 21.97%, indicating double-digit profit growth [1] - The company's gross margin rose to 95.37%, and operating cash flow surged by 96.08% year-on-year, reflecting significant improvement in profitability [1] Product Development - The company is advancing seven research projects, including the upgraded "House Dust Mite Membrane Agent" which entered Phase I clinical trials in March 2025, and the "Dermatitis Diagnostic Patch 02" which received clinical trial approval in May [2] - Iwu Biological holds 20 domestic and international invention patents and invested 61.68 million yuan in R&D, accounting for 12.74% of its revenue, with a research team of over 260 members [2] Market Strategy - The company employs a "scholarly team promotion + commercial distribution" model to enhance awareness of sublingual desensitization therapy among doctors and patients [2] - Iwu Biological has strategically positioned itself in cutting-edge fields such as stem cell therapy and antibiotic resistance, ensuring long-term growth potential [2] Industry Context - The increase in allergy disease prevalence and the rising penetration of desensitization treatments provide a favorable backdrop for Iwu Biological, which is the only company in China with two sublingual desensitization formulations [2]

Core Insights - The Social Security Fund has invested in 313 stocks by the end of Q2, with 20 stocks held for over 20 consecutive quarters [1] - The longest-held stock by the Social Security Fund is Hualu Hengsheng, held for 51 quarters since Q4 2012, with a total holding of 133 million shares, accounting for 6.26% of the circulating shares [1][2] - Among the 20 stocks held for over 5 years, the top holdings by quantity include Changshu Bank, Hualu Hengsheng, and Xiamen Xiangyu, with holdings of 206 million shares, 133 million shares, and 6.39 million shares respectively [2] Holdings Analysis - The Social Security Fund increased its holdings in 8 out of the 20 continuously held stocks by the end of Q2, with significant increases in Hongfa Shares (76.77%), Hangyang Co. (42.03%), and Yilian Network (19.73%) [2] - Conversely, 5 stocks saw a reduction in holdings, with the largest decreases in Zhongqi Shares (-50.14%), Chengyi Pharmaceutical (-8.92%), and Feilihua (-8.70%) [2] Industry Breakdown - The 20 continuously held stocks are concentrated in the basic chemical, pharmaceutical, and electronics industries, with 5, 3, and 2 stocks respectively [3] - The basic chemical sector includes Hualu Hengsheng, Yangnong Chemical, and Lanxiao Technology, while the pharmaceutical sector includes Iwu Biological, Chengyi Pharmaceutical, and New Industry [3] Performance Overview - Among the continuously held stocks, 13 reported year-on-year profit growth in the first half of the year, with notable increases from Jieput (73.84%), Pengding Holdings (57.22%), and Chengyi Pharmaceutical (47.03%) [3] - 7 stocks experienced a decline in net profit, with Zhongqi Shares (-240.99%), Hualu Hengsheng (-29.47%), and Xinwei Communication (-20.18%) showing the largest decreases [3]

Core Viewpoint - Iwubio reported strong financial performance for the first half of 2025, with significant increases in revenue and net profit compared to the previous year, indicating robust growth in the allergy treatment sector [1][3]. Financial Performance - Total revenue for the first half of 2025 reached 484 million yuan, a year-on-year increase of 12.81% [1] - Net profit attributable to shareholders was 177 million yuan, up 18.61% year-on-year [1] - In Q2 2025, total revenue was 256 million yuan, reflecting a 20.07% increase year-on-year, while net profit for the quarter was 103 million yuan, up 42.55% [1] - Gross margin improved to 95.1%, an increase of 0.16% year-on-year, and net margin rose to 35.2%, up 5.93% [1] - Total operating expenses were 202 million yuan, accounting for 41.67% of revenue, a decrease of 1.15% year-on-year [1] Cash Flow and Financial Health - Operating cash flow per share increased by 96.08% to 0.38 yuan, driven by higher cash receipts from sales [3] - The company reported a significant decrease in interest-bearing debt, down 80.21% to 10.13 million yuan, indicating improved financial stability [1][3] - The net increase in cash and cash equivalents was 102.17%, influenced by changes in operating, investing, and financing activities [3] Business Model and Market Position - Iwubio focuses on the treatment of allergic diseases, leveraging its R&D capabilities to develop desensitization products [5] - The company’s business model is primarily driven by marketing efforts, which require careful analysis of the underlying drivers [3] - The company has a historical median ROIC of 19.19%, indicating strong investment returns over the past decade [3] Future Outlook - Analysts project that Iwubio's revenue for 2025 will reach 352 million yuan, with an average earnings per share estimate of 0.67 yuan [4]

Core Viewpoint - Iwubio (300357.SZ) reported a strong mid-year performance with double-digit growth in both revenue and profit, driven by its core products and a robust innovation system [1][2][3] Financial Performance - Revenue increased to 484 million yuan, a year-on-year growth of 12.81% - Net profit attributable to shareholders reached 177 million yuan, with a year-on-year increase of 18.61% - Deducting non-recurring gains, net profit grew by 21.97% to 173 million yuan - Gross margin improved to 95.37%, and operating cash flow surged by 96.08% to 200 million yuan [1][3][4] Product Performance - The main product, "Dust Mite Drops," generated sales of 455 million yuan, up 10.51% year-on-year - "Artemisia Pollen Drops" sales reached 21.02 million yuan, a growth of 71.37% - "Skin Prick Test Kit" sales amounted to 6.33 million yuan, increasing by 104.38% [2][3][4] R&D and Innovation - R&D investment accounted for 12.74% of revenue, totaling 61.68 million yuan - The company has 7 products in the pipeline, including "House Dust Mite Membrane" which is in Phase I clinical trials - Iwubio holds 13 valid Chinese invention patents and 7 foreign invention patents [4][5][6] Market Strategy - The company employs an efficient sales model combining academic promotion and commercial distribution - Iwubio is expanding its strategic focus to include stem cell therapy and natural medicines, laying a foundation for long-term growth [6]

Financial Performance - In the first half of 2025, the company achieved operating revenue of ¥484,236,510.36, representing a year-on-year growth of 12.81% [2] - The net profit attributable to shareholders was ¥177,008,721.63, an increase of 18.61% compared to the same period last year [2] - Sales revenue from dust mite drops was ¥454,655,215.07, up 10.51% year-on-year [2] - Sales revenue from Artemisia pollen sublingual drops reached ¥21,020,536.26, marking a significant growth of 71.37% [2] - Sales revenue from skin prick solution was ¥6,327,765.88, showing a remarkable increase of 104.38% [3] R&D Pipeline - The "Dust Mite Membrane Agent" entered Phase I clinical trials in March 2025, aimed at enhancing the existing dust mite drop product [3] - The "Dermatitis Diagnostic Patch 02" received approval for clinical trials in May 2025 and entered Phase I trials in August 2025 [3] - The company is expanding its product pipeline in the field of allergic disease diagnostics, addressing various types of allergens [3][4] Sales and Marketing Strategy - The company has promoted a group of young sales managers since the second half of last year, aiming to enhance regional responsibilities and management efficiency [4] - The positioning of skin prick solutions is evolving from auxiliary desensitization products to primary allergen screening tools [4] Future Outlook - The sales outlook for the second half of 2025 for Artemisia pollen sublingual drops is anticipated to be positive, with further details to be disclosed in upcoming reports [5] - The company aims to enrich its pipeline of allergen products and enhance market competitiveness [6][10] - Ongoing research includes mesenchymal stem cell therapies and new antibiotics for drug-resistant tuberculosis, currently in preclinical stages [7][10]

| 代码 | 简称 | 连续持有期数 | 社保基金家数 | 持股量（万股） | 环比（%） | 占流通股比例（%） | | --- | --- | --- | --- | --- | --- | --- | | 600486 | 扬农化工 | 43 | 1 | 1630.80 | -4.30 | 4.05 | | 300357 | 我武生物 | 43 | 1 | 2608.11 | 不变 | 5.39 | | 600031 | 三一重工 | 33 | 2 | 17139.44 | -2.50 | 2.02 | | 601128 | 常熟银行 | 30 | 4 | 27779.13 | -0.57 | 8.38 | | 300487 | 蓝晓科技 | 29 | 1 | 494.99 | 不变 | 1.61 | | 300196 | 长海股份 | 28 | 1 | 412.29 | 不变 | 1.68 | | 300685 | 艾德生物 | 26 | 1 | 512.15 | -52.54 | 1.31 | | 002847 | 盐津铺子 | 23 | 1 | 171.28 | -53.00 | 0.70 | | ...

2025年8月22日，我武生物(300357.SZ)发布2025年中报。 公司营业总收入为4.84亿元，较去年同报告期营业总收入增加5497.95万元，实现2年连续上涨，同比较 去年同期上涨12.81%。归母净利润为1.77亿元，较去年同报告期归母净利润增加2777.77万元，实现2年 连续上涨，同比较去年同期上涨18.61%。经营活动现金净流入为2.01亿元，较去年同报告期经营活动现 金净流入增加9825.40万元，同比较去年同期上涨96.08%。 公司最新总资产周转率为0.18次，较去年同期总资产周转率增加0.01次，同比较去年同期上涨7.57%。 最新存货周转率为0.42次，较去年同期存货周转率增加0.06次，同比较去年同期上涨15.82%。 公司股东户数为3.46万户，前十大股东持股数量为3.06亿股，占总股本比例为58.41%，前十大股东持股 情况如下： | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | I | 浙江我武管理咨询有限公司 | 38.86% | | 2 胡康熙 | | 8.35% | | య | 全国社保基金 -- 二组合 | 4.98% | | 4 ...

Core Viewpoint - Iwubio announced the convening of its 13th meeting of the 5th Board of Directors on August 21, 2025, to review various proposals, including amendments to existing documents [2] Financial Performance - For the first half of 2025, Iwubio reported that its revenue composition was 99.59% from pharmaceutical manufacturing and 0.41% from other businesses [2]